Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis – Not always self-limiting,fully reversible or predictable

Abstract

Get full access to this article

View all access options for this article.

References

Ranganathan

Kaunzner

Foster

et al . Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis. Mult Scler 2018; 24: 552–554.

Cuker

Coles

Sullivan

et al . A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood 2011; 118(24): 6299–6305.

George

Aster

. Drug-induced thrombocytopenia: Pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program 2009; 153–158. doi: 10.1182/asheducation-2009.1.153.

Ruck

Bittner

Wiendl

et al . Alemtuzumab in multiple sclerosis: Mechanism of action and beyond. Int J Mol Sci 2015; 16(7): 16414–16439.

Lehman

Rustagi

et al . Complement-mediated autoimmune thrombocytopenia. Monoclonal IgM antiplatelet antibody associated with lymphoreticular malignant disease. N Engl J Med 1987; 316(4): 194–198.

Summary of Product Characteristics. Lemtrada 12 mg concentrate for solution for infusion, http://www.medicines.ie/medicine/16052/SPC/LEMTRADA+12+mg+concentrate+for+solution+for+infusion/ (2016, accessed 19 April 2017).